When will LIMN stock report earnings and why does it matter

LIMN stock has an earnings announcement scheduled for 12 Feb 2026. The report matters because Liminatus is clinical-stage; management comments on trials and cash runway will drive share moves and dilution risk

What is Meyka AI's forecast for LIMN stock

Meyka AI's forecast model projects a 12-month target of $2.40 USD for LIMN stock, implying a 30.43% upside from the current $1.84. Forecasts are model-based projections and not guarantees

What are the main risks for LIMN stock investors

Main risks for LIMN stock include continued cash burn, dilution from capital raises, clinical trial setbacks, and the small-company operational footprint, given only 3 full-time employees

How did LIMN stock trade today and what signals should traders watch

LIMN stock traded heavy volume at 44,334,182.00 shares and closed at $1.84 USD. Traders should watch RSI (36.30), support at $1.60, resistance at $2.63, and upcoming earnings on 12 Feb 2026

US Stocks

LIMN Liminatus Pharma (NASDAQ) falls 10.24% to $1.84 on 06 Feb 2026: earnings on 12 Feb could reset outlook

ByHuzaifa Zahoor February 7, 2026

LIMN stock closed the NASDAQ session at $1.84, down 10.24% on heavy volume ahead of an earnings update scheduled for 12 Feb 2026. Investors traded 44,334,182.00 shares today versus an average of 4,597,422.00, pushing the relative volume to 9.46 and flagging short-term volatility. Liminatus Pharma, Inc. Class A Common Stock (LIMN) is a clinical-stage immuno-oncology company based in the United States, and the upcoming earnings announcement could materially affect sentiment given the company’s negative EPS of -0.16 and a trailing PE of -11.50. We examine the financials, technicals, Meyka AI grade, and a model forecast to frame the risk-reward into earnings